Female BRCA mutation carriers with a preference for prophylactic mastectomy are more likely to participate an educational-support group and to proceed with the preferred intervention within 2 years

Familial Cancer

Volumn 9, Issue 2, 2010, Pages 213-220

  Landsbergen, Karin M ^a   Prins, Judith B ^a   Kamm, Yvonne J L ^a   Brunner, Han G ^a   Hoogerbrugge, Nicoline ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BRCA; Breast cancer risk management; Breast cancer surveillance; Educational support group; Oncology; Prophylactic mastectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; HEALTH EDUCATION; HETEROZYGOTE; HUMAN; MASTECTOMY; ONCOGENE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPHYLAXIS; RISK MANAGEMENT; SUPPORT GROUP;

BRCA1 PROTEIN; BREAST NEOPLASMS; CHOICE BEHAVIOR; DECISION MAKING; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOTYPE; HUMANS; MASTECTOMY; NEOPLASM PROTEINS; OVARIECTOMY; PATIENT SATISFACTION; POPULATION SURVEILLANCE; PROGNOSIS; RISK ASSESSMENT; RISK MANAGEMENT; SELF-HELP GROUPS;

EID: 77955049192     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-009-9311-3     Document Type: Article

References (28)

1. Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117-1130
2. Brose MS, Rebbeck TR, Calzone KA et al (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365-1372
3. Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329-1333
4. Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62:676-689
5. Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408
6. Thompson D, Easton DF (2002) Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358-1365 (Pubitemid 35154140)
7. Chen S, Iversen ES, Friebel T et al (2006) Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 24:863-871
8. Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A (2007) Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer 121:225-231
9. National Institute for Health and Clinical Excellence (NHS) NICE Guideline Familial Breast Cancer. 25-110-2006
10. Warner E, Plewes DB, Hill KA et al (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317-1325 (Pubitemid 39223222)
11. Hartmann LC, Schaid DJ, Woods JE et al (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77-84
12. Meijers-Heijboer H, van GB, van Putten WL et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159-164
13. Rebbeck TR, Friebel T, Lynch HT et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 22:1055-1062 (Pubitemid 41095038)
14. Lerman C, Hughes C, Croyle RT et al (2000) Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 31:75-80
15. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT et al (2000) Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 355:2015-2020
16. Metcalfe KA, Snyder C, Seidel J et al (2005) The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer 4:97-103
17. Scheuer L, Kauff N, Robson M et al (2002) Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20:1260-1268
18. Botkin JR, Smith KR, Croyle RT et al (2003) Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 118A:201-209
19. Foster C, Watson M, Eeles R et al (2007) Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year followup. Br J Cancer 96:718-724
20. Bleiker EM, Grosfeld FJ, Hahn DE et al (2001) Psychosocial care in family cancer clinics in The Netherlands: a brief report. Patient Educ Couns 43:205-209
21. Meiser B, Butow P, Friedlander M et al (2000) Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. J Clin Oncol 18:2250-2257 (Pubitemid 30350217)
22. Lostumbo L, Carbine N, Wallace J et al. (2004) Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 4:CD002748. Review
23. Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M et al (2003) Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol 21:1675-1681
24. van Dijk S, Otten W, Zoeteweij MW et al (2003) Genetic counselling and the intention to undergo prophylactic mastectomy: effects of a breast cancer risk assessment. Br J Cancer 88:1675-1681
25. van Dijk S, van Roosmalen MS, Otten W et al (2008) Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret. J Clin Oncol 26:2358-2363
26. van Oostrom I, Meijers-Heijboer H, Lodder LN et al (2003) Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol 21:3867-3874
27. Beattie MS, Crawford B, Lin F et al (2009) Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomarkers 13:51-56
28. Hoogerbrugge N, Kamm YJ, Bult P et al (2008) The impact of a false-positive MRI on the choice for mastectomy in BRCA mutation carriers is limited. Ann Oncol 19:655-659